ITGAX and neoplasm: Minkov et al. found that both CD123+ lymphoid/plasmacytoid and CD11c+ myeloid DCs were important components of the anti-tumor immunity in non-small cell lung cancer (NSCLC) patients and their level could be a potential predictive factor for tumor development [65].